Close X
Monday, December 30, 2024
ADVT 
International

Indian-origin man shot dead execution-style in New York

Darpan News Desk IANS, 27 Jun, 2022 04:45 PM
  • Indian-origin man shot dead execution-style in New York

New York, June 27 (IANS) An Indian-origin man was shot dead execution-style as he was sitting in a jeep near his home in New York, according to media reports.

After the shooting on Saturday afternoon, Satnam Singh, 31, was taken to a local hospital where doctors declared him dead, the New York Daily News reported quoting police.

The incident happened in the South Ozone Park neighbourhood, which is next to Richmond Hill where two Sikh men had been assaulted in April in what police classified as hate crimes.

Both areas have large numbers of people of Indian origin.

The News said that there was a discrepancy between the police and eyewitness accounts of Satnam Singh's shooting.

It said that according to police, the shooter came on foot and shot him as he sat in the jeep, but a neighbour said the assailant had fired from a car and that her home security camera had captured the incident.

AmNY news site said that as of Sunday morning there has been no arrest and police were unsure of the motive.

The News, quoting police sources, said that Satnam Singh had borrowed the jeep from a friend and detectives were looking into whether he was the shooter's intended target or had been mistakenly killed by someone who actually wanted to attack the owner of the vehicle.

In April, two Sikhs had their turbans knocked off and robbed in separate incidents in Richmond Hill.

Police arrested two men in connection with those attacks and charged them with hate crimes.

MORE International ARTICLES

AstraZeneca resuming US testing of COVID-19 vaccine

AstraZeneca resuming US testing of COVID-19 vaccine
The AstraZenca vaccine, developed with Oxford University, is one of several coronavirus vaccine candidates in final-stage testing around the world.

AstraZeneca resuming US testing of COVID-19 vaccine

FDA approves first COVID-19 drug: antiviral remdesivir

FDA approves first COVID-19 drug: antiviral remdesivir
The drug, which California-based Gilead Sciences Inc. is calling Veklury, cut the time to recovery by five days — from 15 days to 10 on average — in a large study led by the U.S. National Institutes of Health.

FDA approves first COVID-19 drug: antiviral remdesivir

Here we go again: Trump, Biden reprise debate duel

Here we go again: Trump, Biden reprise debate duel
Instead, they're bracing for another show of vintage Trump, one in which he'll seek to be heard even in spite of his muted microphone.

Here we go again: Trump, Biden reprise debate duel

Getting ready for the gong show: Trump v. Biden II

Getting ready for the gong show: Trump v. Biden II
It's the sequel to last month's debate horror show between Donald Trump and Joe Biden, an invective-laced 90 minutes that laid bare the depths to which political discourse can sink in an American election year.

Getting ready for the gong show: Trump v. Biden II

US overdose deaths appear to rise amid coronavirus pandemic

US overdose deaths appear to rise amid coronavirus pandemic
Davidson lost his job. He started staying home alone in his apartment near Georgetown, Kentucky — depressed and yearning for his recovery support group that had stopped gathering in person, said his cousin Melanie Wyatt.

US overdose deaths appear to rise amid coronavirus pandemic

Pfizer: Mid-November earliest it can seek virus vaccine OK

Pfizer: Mid-November earliest it can seek virus vaccine OK
Another leading U.S. contender, Moderna Inc., previously announced the earliest it could seek authorization of its own vaccine would be Nov. 25.

Pfizer: Mid-November earliest it can seek virus vaccine OK